Cosmos Health Inc. announced on Monday that its subsidiary Cana Laboratories has secured a five‑year manufacturing agreement with Target Pharma. The contract covers the production of approximately 5.2 million pharmaceutical units, including the topical antibiotic mupirocin and the acne treatment tretin, with Target Pharma slated to order about 1.04 million units each year.
The deal follows a similar five‑year contract signed with Viofar on September 11. Cana now reports a total orderbook exceeding 32.7 million units, up from more than 12 million units earlier in the year, reflecting a 31% increase since June 2026. In September alone, the subsidiary added 7.7 million contracted units through the two agreements.
Cana’s product portfolio has expanded to 11 therapeutic categories, up from nine in June, after adding cardiovascular and anti‑infective lines. The company operates a 54,000‑square‑foot facility in Athens that is licensed under European Good Manufacturing Practices and certified by the European Medicines Agency.
Cosmos Health has invested roughly $5.5 million in facility upgrades, including new manufacturing equipment, IT infrastructure, quality‑management systems and a capsule‑filling line. The division aims to generate more than $10 million in recurring annual profit once operating at full capacity.
"We have added 7.7 million contracted units this month alone and grown the orderbook 31% since June," said Greg Siokas, CEO of Cosmos Health.
